Sphere Bio Launches Cyto-Cellect IgG Kappa and Viability Assay Kit for Single-Cell Selection
Sphere Bio, a leader in picodroplet-based microfluidics solutions for functional single-cell analysis and isolation, has unveiled the Cyto-Cellect® Human IgG Kappa and Viability Assay Kit. This is the first multiplexed assay developed specifically for the company’s innovative Cyto-Mine® Chroma platform. The launch of this kit marks a significant milestone in advancing single-cell screening, enabling faster workflows, improved cell viability, and more efficient research processes.
Advanced Technology for High-Throughput Screening
The Cyto-Mine Chroma platform is designed to enhance single-cell selection through the use of fluorescence-based assays in picodroplets. By detecting secreted, surface, or intracellular markers, the system can sort individual cells based on various criteria. With the introduction of the new multiplexing capabilities, the Cyto-Cellect Human IgG Kappa and Viability Assay Kit elevates this process by allowing researchers to simultaneously analyze antibody secretion and cell viability in a single, streamlined workflow.
This advanced technology enables high-throughput screening of viable, high-producing clones, making it easier to identify the most productive cells. One of the key advantages of the new assay is its ability to detect both antibody production and cell viability simultaneously. By assessing both factors, the assay reduces the risk of selecting unhealthy cells, which can be costly and time-consuming in later stages of research. Preliminary data show that about five percent of selected high-producing clones tend to be apoptotic (dying or dead). Screening out these non-viable cells early in the process significantly improves the quality of the selected clones and ensures that only the highest-performing cells are carried forward for further development.
Key Benefits and Features of the New Assay Kit
The Cyto-Cellect Human IgG Kappa and Viability Assay Kit, in conjunction with the Cyto-Mine Chroma platform, offers several compelling features that make it a breakthrough tool for single-cell analysis and development:
- Multiplexing Capabilities: The kit enables the simultaneous detection of productivity and viability markers, ensuring optimal selection outcomes for researchers.
- Streamlined Workflows: By automating the process, the new kit reduces development timelines from months to just hours, accelerating research and shortening time-to-results.
- Unprecedented Throughput and Cost Efficiency: The platform offers significantly higher throughput and lower operational costs when compared to traditional methods of cell screening and selection.
- Monoclonality Assurance: The assay ensures the selected clones are monoclonal, providing confidence in the consistency and purity of the cells for further analysis or therapeutic development.
The launch of this new product aligns with Sphere Bio’s commitment to providing cutting-edge solutions that enhance cell line development, allowing for faster, more reliable results. The Cyto-Cellect assay kit builds on the company’s goal of setting new industry standards for efficiency and reliability in single-cell workflows.
Transforming Single-Cell Workflows
Dr. Xin Liu, Senior Product Manager for Assays and Applications at Sphere Bio, shared her excitement about the launch, saying, “Our new assay kit is a game-changer for single-cell workflows. By integrating viability assessment with antibody detection, we can ensure that only the healthiest, most productive cells are selected, significantly improving the efficiency and outcomes of our customers’ research.” This innovation is expected to have a profound impact on various applications, including therapeutic antibody production, cell therapy development, and other cutting-edge research fields that rely on single-cell isolation.
Dr. Maryam Ahmadi, Director of Science at Sphere Bio, also expressed her enthusiasm for the launch, noting, “The Cyto-Cellect Human IgG Kappa and Viability Assay Kit leverages the advanced capabilities of Cyto-Mine Chroma to deliver unparalleled precision in single-cell analysis. This new assay is the first in our roadmap of multiplex assays designed to work seamlessly with Chroma, and it represents a significant step in bringing advanced multiplexing capabilities to our customers. With this expanding portfolio of tools, we are helping to accelerate scientific discovery and enhance the efficiency of single-cell research.”
Enhancing the Research Landscape
The combination of the Cyto-Cellect assay kit and Cyto-Mine Chroma platform is poised to transform the way researchers approach single-cell selection and analysis. The ability to assess both cell productivity and viability simultaneously offers a powerful tool for advancing cell-based research and development. This will not only streamline workflows but also improve the quality of the selected clones, ensuring that only the most viable and productive cells move forward for further development.
By improving the quality and efficiency of single-cell analysis, Sphere Bio continues to lead the way in providing innovative solutions for cell line development. As research in biotechnology, cell therapies, and antibody production continues to grow, the need for reliable, high-throughput screening tools will only increase. Sphere Bio’s Cyto-Cellect Human IgG Kappa and Viability Assay Kit is a step toward meeting these demands, providing researchers with the tools they need to make faster, more informed decisions.
